SGA
BMRN icon

Sector Gamma AS’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sector Gamma AS’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6M Buy
239,918
+41,413
+21% +$2.41M 3.2% 9
2025
Q4 		$11.8M Buy
198,505
+22,653
+13% +$1.23M 2.69% 16
2025
Q3 		$9.52M Buy
175,852
+53,504
+44% +$3.06M 2.36% 13
2025
Q2 		$6.73M Sell
122,348
-15,000
-11% -$883K 2.2% 18
2025
Q1 		$9.71M Sell
137,348
-80,000
-37% -$5.38M 3.11% 13
2024
Q4 		$14.3M Buy
217,348
+27,000
+14% +$1.81M 4.91% 7
2024
Q3 		$13.4M Buy
190,348
+127,000
+200% +$10.6M 4.06% 10
2024
Q2 		$5.22M Sell
63,348
-18,068
-22% -$1.5M 1.95% 21
2024
Q1 		$7.11M Sell
81,416
-4,831
-6% -$432K 2% 19
2023
Q4 		$8.32M Sell
86,247
-9,801
-10% -$867K 2.02% 19
2023
Q3 		$8.5M Sell
96,048
-66,620
-41% -$5.93M 2.17% 18
2023
Q2 		$14.1M Buy
162,668
+6,318
+4% +$595K 3.15% 13
2023
Q1 		$15.2M Buy
156,350
+1,341
+0.9% +$139K 3.69% 10
2022
Q4 		$16M Buy
155,009
+45,405
+41% +$4.26M 3.67% 11
2022
Q3 		$9.29M Buy
109,604
+4,345
+4% +$387K 2.39% 16
2022
Q2 		$8.72M Buy
105,259
+25,500
+32% +$2.03M 1.95% 20
2022
Q1 		$6.15M Sell
79,759
-33,789
-30% -$2.83M 1.34% 27
2021
Q4 		$10M Buy
+113,548
New +$9.37M 2.36% 18
2021
Q3 		– Sell
-68,964
Closed -$5.75M – 32
2021
Q2 		$5.75M Sell
68,964
-22,750
-25% -$1.8M 1.02% 29
2021
Q1 		$6.92M Buy
+91,714
New +$7.49M 1.27% 26
2020
Q3 		– Sell
-108,482
Closed -$13.4M – 29
2020
Q2 		$13.4M Sell
108,482
-31,100
-22% -$3.09M 2.76% 17
2020
Q1 		$11.8M Buy
139,582
+64,679
+86% +$5.57M 2.51% 18
2019
Q4 		$6.33M Buy
+74,903
New +$5.66M 1.01% 29

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sector Gamma AS's BMRN Position: Q1 2026 in Review

Sector Gamma AS increased its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q1 2026, buying an estimated $2.41M and bringing the position to 239,918 shares worth $13.6M. The position accounts for 3.2% of the portfolio, ranked #9.

Sector Gamma AS first reported a position in BMRN in Q4 2019 and has held it in 23 quarters since. The position peaked at $16M in Q4 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Sector Gamma AS held 239,918 shares of BioMarin Pharmaceuticals worth $13.6M as of Q1 2026.
  • Sector Gamma AS bought 41,413 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.41M.
  • BioMarin Pharmaceuticals made up 3.2% of Sector Gamma AS's portfolio in Q1 2026, its #9 holding.
  • Sector Gamma AS first reported a position in BioMarin Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
  • Sector Gamma AS's BioMarin Pharmaceuticals position peaked at $16M in Q4 2022.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Sector Gamma AS's 13F filing for Q1 2026, filed 7 May 2026.